Lai Kai Pharmaceutical-B (02105): LAE103 successfully completed phase I SAD study in overweight or obese subjects

Zhitong Finance App News, Laikai Pharmaceutical-B (02105) announced that the Group has successfully completed a Phase I single-dose escalation study (SAD study) of LAE103 (ActRIIb monoclonal antibody) in overweight or obese subjects in Australia. The SAD study was a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic properties of LAE103 (subcutaneous injection) in overweight or obese subjects.

LAE103 is well tolerated and safe in a single subcutaneous administration. No serious adverse events have been reported, and there have been no reports of discontinuation of administration due to adverse events. The study observed clear target binding and changes in expected pharmacodynamic biomarkers. The single-dose LAE103 showed pharmacokinetic characteristics related to dose ratios, as well as clear pharmacokinetic/pharmacodynamic correlations, proving that LAE103 has therapeutic potential for subcutaneous administration once a month and excellent drug developability.